Bokf Na Has $1.11 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Bokf Na lifted its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 17.3% during the 2nd quarter, Holdings Channel reports. The fund owned 26,213 shares of the medical research company’s stock after acquiring an additional 3,875 shares during the quarter. Bokf Na’s holdings in Exact Sciences were worth $1,108,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. National Bank of Canada FI lifted its holdings in Exact Sciences by 30.9% during the 4th quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock worth $63,000 after buying an additional 200 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Exact Sciences by 3.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 695,542 shares of the medical research company’s stock worth $51,466,000 after buying an additional 24,259 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in Exact Sciences by 5.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 14,901 shares of the medical research company’s stock worth $1,102,000 after buying an additional 759 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Exact Sciences by 36.7% during the 4th quarter. Quadrant Capital Group LLC now owns 1,230 shares of the medical research company’s stock worth $91,000 after buying an additional 330 shares in the last quarter. Finally, Kingsview Wealth Management LLC lifted its holdings in Exact Sciences by 24.0% during the 4th quarter. Kingsview Wealth Management LLC now owns 12,491 shares of the medical research company’s stock worth $924,000 after buying an additional 2,420 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EXAS. BTIG Research cut their price target on Exact Sciences from $80.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, June 26th. Stifel Nicolaus cut their price target on Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Evercore ISI cut their price target on Exact Sciences from $80.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Jefferies Financial Group began coverage on Exact Sciences in a research note on Monday, June 3rd. They issued a “buy” rating and a $75.00 price target on the stock. Finally, Wells Fargo & Company began coverage on Exact Sciences in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $78.14.

Exact Sciences Price Performance

EXAS opened at $65.54 on Monday. The company has a fifty day simple moving average of $54.89 and a 200 day simple moving average of $55.44. The stock has a market cap of $12.11 billion, a P/E ratio of -49.65 and a beta of 1.26. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The firm had revenue of $699.26 million during the quarter, compared to analysts’ expectations of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The company’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.45) EPS. On average, research analysts expect that Exact Sciences Co. will post -0.87 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.